NHS-MMAF - CAS# 1404073-19-3 mecrolimus InChi: InChI=1S/C24H20N2O3/c1-17-7-5-9-19(13-17)16-29-21-12-6-8-18(14-21)15-22-23(27)25-26(24(22)28)20-10-3-2-4-11-20/h2-15H

InChi: InChI=1S/C24H20N2O3/c1-17-7-5-9-19(13-17)16-29-21-12-6-8-18(14-21)15-22-23(27)25-26(24(22)28)20-10-3-2-4-11-20/h2-15H

8'-trihydroxy-2'

Linifanib could cause a decrease in S and G2-M phases with a corresponding increase in the sub-G0-G1 apoptotic population in MV4-11 cells

33S)-15-[[(2S)-2-[[(2S)-1-[(2S)-2-acetamido-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-(3-chlorophenyl)propanoyl]amino]-6-(4-aminobutyl)-24-benzyl-3-butyl-9-(3-carbamimidamidopropyl)-27-(hydroxymethyl)-30-methyl-12-(2-methylpropyl)-2

InChiKey: DYDCUQKUCUHJBH-UWTATZPHSA-N

NHS-MMAF - CAS# 1404073-19-3 mecrolimus InChi: InChI=1S/C24H20N2O3/c1-17-7-5-9-19(13-17)16-29-21-12-6-8-18(14-21)15-22-23(27)25-26(24(22)28)20-10-3-2-4-11-20/h2-15HNHS MMAF is a modified MMAF extracted from patent WO2012143499, intermediat 219. MMAF is a potent tubulin polymerization inhibitor and is used as a antitumor agent Product information CAS Number: 1404073 19 3 Molecular Weight: 943. 18 Formula: C49H78N6O12 Chemical Name: ((2R, 3R) 3 ((S) 1 ((3R, 4S, 5S) 4 ((S) 2 ((S) 2 ((6 ((2, 5 dioxopyrrolidin 1 yl)oxy) 6 oxohexyl)(methyl)amino) 3 methylbutanamido) N, 3 dimethylbutanamido) 3 methoxy 5